VIVS

Business Context and Reporting Period

Company: VivoSim Labs, Inc. (formerly Organovo Holdings, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2025
Business Model Shift: The Company transitioned from a clinical-stage biotechnology firm focused on developing FXR314 for inflammatory bowel disease to a pharmaceutical and biotechnology services company. The new model focuses on providing drug testing services using 3D human tissue models (liver and intestine) to predict toxicity. On March 25, 2025, the Company sold its FXR program to Eli Lilly and Company for $10.0 million upfront plus potential milestones. The corporate name changed to VivoSim Labs, Inc. effective April 24, 2025.

Key Financial Metrics

Other Key Data:

• Other Income: $10.130 million (primarily due to the $10.0 million gain on the sale of the FXR program).
• Stock-Based Compensation: $0.532 million (down from $1.508 million in 2024).
• Outstanding Shares: 1,898,068 (as of March 31, 2025, post 1-for-12 reverse stock split).

Material Changes vs. Prior Period

• Strategic Pivot: Discontinued internal clinical development of FXR314 and sold the program to Eli Lilly. Shifted focus entirely to 3D tissue services (NAMkind liver and intestine models).
• Asset Sale: Recognized a $10.0 million gain on the sale of the FXR program, significantly reducing the net loss compared to the prior year.
• Expense Reduction: Operating expenses decreased by approximately $2.4 million year-over-year, driven by a 20% reduction in SG&A and a 9% reduction in R&D expenses due to headcount reductions and cost-cutting measures.
• Liquidity Improvement: Cash and cash equivalents increased from $2.9 million to $11.3 million, bolstered by the FXR sale proceeds ($9.0 million received at closing) and equity financing activities.
• Reverse Stock Split: Effected a 1-for-12 reverse stock split on March 21, 2025, to regain compliance with Nasdaq listing requirements.

Guidance, Outlook, Risks, and Contingencies

Going Concern: Management and the independent auditors have expressed substantial doubt about the Company's ability to continue as a going concern for at least one year following the issuance of the financial statements. The Company expects to incur substantial additional operating losses and will require significant additional funding to support future operations.

Outlook:

• Anticipates accelerated adoption of human tissue models following FDA announcements regarding non-animal testing methods.
• Projects total operating expenses for the fiscal year ending March 31, 2026, to be approximately $10.1 million.
• Plans to raise additional capital through equity offerings (including an ATM program) or debt financing.

Risks and Contingencies:

• Nasdaq Compliance: The Company received deficiency notices regarding minimum bid price and stockholders' equity. While compliance was demonstrated following the reverse stock split, the Company is subject to a one-year Mandatory Panel Monitor.
• Litigation: H.C. Wainwright & Co., LLC filed a complaint alleging breach of a tail financing provision. The Company has accrued $0.6 million for this contingency.
• Capital Requirements: Failure to secure additional financing could force the Company to curtail or cease operations.
• Intellectual Property: Reliance on licensed IP from the University of Missouri and others; potential challenges to patent validity.

Investor Verification Checklist

• Going Concern Status: Verify the Company's ability to secure the substantial additional funding required to operate beyond the next 12 months.
• FXR Milestone Payments: Confirm the likelihood of receiving the potential $50.0 million in future milestone payments from Eli Lilly, which are contingent on regulatory and commercial success.
• Nasdaq Listing: Monitor the Company's compliance with Nasdaq listing rules during the one-year monitoring period following the reverse stock split.
• Service Revenue Growth: Assess the traction of the new 3D tissue services business model, as historical revenue has been negligible ($0.144 million).
• Litigation Outcome: Track the resolution of the H.C. Wainwright lawsuit and potential additional liabilities beyond the $0.6 million accrual.